- Optimize Patient/Site Experience
- Increase Diversity/Access to Clinical Trials
- Predictive Safety Monitoring
- Pharmacovigilance Paradigm Shift
- Improve Benefit/Risk Profile
- Optimize Path to Commercialization
- Accelerate Path to Effectiveness
The Intrepid Partner Program is designed to extend physIQ’s capabilities to the industry through participating Contract Research Organizations (CROs), Academic Research Organizations (AROs) and other technology solution companies. The program provides a distinct advantage to its partners when competing for the business of both large and small life science companies alike.
The unique value proposition of physIQ’s solutions and services significantly enhances our partners’ ability to maximize ROI while fundamentally making clinical trials safer while improving patient journeys and outcomes.
accelerateIQ captures high quality, objective data to expand your clinical trial capabilities.
Decentralized trials have the potential to expand patient pools and obtain more data to make better decisions. accelerateIQ unlocks this potential by providing continuous remote data collection which increases available information while reducing site visits.
The physIQ platform makes monitoring patients in clinical trials an ongoing, continuous process whereby trial monitors can have access to near real-time data and reduce the need for face-to-face interactions.
Risk-based monitoring focuses activities to the evolving areas of greatest need which have the most potential to impact patient safety and data quality. With continuous data from accelerateIQ, you can uncover patient concerns and trial problems in near real time.
By collecting and analyzing physiological data and feeding that into a predictive analytics platform, accelerateIQ can help you anticipate safety concerns rather than react to them.
Built on the leading platform for continuous wearable sensor data